Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

INDIANAPOLIS, Aug. 26, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults... Biopharmaceuticals, FDA Eli Lilly, Taltz, ixekizumab, ankylosing spondylitis

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2045302

Source: HSMN NewsFeed - August 26, 2019 Category: Pharmaceuticals Source Type: news

More News: Ankylosing Spondylitis | Food and Drug Administration (FDA) | Marketing | Pharmaceuticals | Radiography